Mylan N.V.  has announced the pricing of the underwritten public offering of 35 million ordinary shares held by certain subsidiaries of Abbott Laboratories (Abbott), at $58.35 per share. Abbott has also granted the underwriters an option to purchase an additional 5.3 million ordinary shares. The net proceeds from the Offering will be approximately $1.99 billion (or $2.29 billion if the option is exercised) after estimated underwriting discounts, commissions and offering expenses.

Mylan will not sell any ordinary shares in the Offering and will not receive any of the proceeds from the Offering. The 35 million ordinary shares being sold (or 40.3 million ordinary shares if the underwriters' option is exercised) represent 31.8 per cent or (36.6 per cent if the option is exercised) of the 110 million ordinary shares currently owned by Abbott.

Morgan Stanley & Co. LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the Offering. A shelf registration statement (including prospectus) relating to the ordinary shares to be sold in the Offering is effective with the Securities and Exchange Commission.

Mylan N.V. is considered the successor to Mylan Inc. for certain purposes under the Securities Act of 1933 and the Securities Exchange Act of 1934.